ARTICLE | Financial News
Syncona leads CHF35M A round for Anaveon
March 1, 2019 8:09 PM UTC
Anaveon AG (Zurich, Switzerland) closed the first undisclosed tranche of a CHF35 million ($35 million) series A round on Feb. 26 to help bring its biologic IL-2 receptor agonists into the clinic. Syncona Ltd. (LSE:SYNC) is leading the round with a CHF28 million ($28 million) commitment. Novartis Venture Fund is also participating.
The company spun out of the University of Zurich in 2017 with seed funding from UZH Life Sciences Fund and BaseLaunch accelerator...
BCIQ Target Profiles